House-passed legislation would ban the use of quality-adjusted life-years, a metric that has gained worldwide acceptance as a ...
This past fall, ubiquitous Medicare Advantage ads on television, radio, social media, and across the internet looked a little ...
As large corporate entities and financial investors accrue more power in health care, states considering reinvigorating an ...
We propose a transparent framework for CMS to implement Medicare drug price negotiation in a manner that results in credible, ...
The COVID-19 pandemic demonstrated that US hospital and health care systems were ill-prepared for the surge of patients who ...
The A.C.C.E.S.S. AI Model is a framework for multidisciplinary stakeholders to collectively engage communities, identify ...
On April 26, 2024, the Department of Health and Human Services published a final rule to strengthen privacy protections for ...
Repurposing a Food and Drug Administration (FDA)-approved drug for a new use has been informally practiced for years. In fact ...
A new health policy brief from Health Affairs, with support from the Robert Wood Johnson Foundation, is titled “Pillars, ...
In their article, Philip Gruppuso, MD, and Eli Adashi, MD, MS, highlight some important inequities that necessitate the Fair ...
Health Affairs' Jeff Byers interviews Jack Hoadley from Georgetown University about the final rule for the Medicare Advantage and Medicare Part D programs for 2025. Read the new Health Policy ...
Evidence On Private Equity Suggests That Containing Costs And Improving Outcomes May Go Hand-In-Hand
As policy makers continue to debate health care pricing reform, they should be aware of the facts: Private equity’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results